Under the JV, ImmunityBio and Amyris combined their key vaccine technology and production expertise. Credit: Spencer Davis on Unsplash.

ImmunityBio and Amyris have concluded a joint venture (JV) agreement that was announced earlier to speed up the marketing of a next-generation vaccine for Covid-19.

The companies, which signed the 50:50 arrangement in November last year, merged their key vaccine technology and production expertise through the JV.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

On concluding the human trials and obtaining regulatory approval, the JV intends to commence supply of the second-generation Covid-19 shot this year.

This move is aimed at offering access to underserved regions globally where present vaccine technology is challenged due to limitations in price as well as supply chain.

ImmunityBio executive chairman and global chief scientific and medical officer Patrick Soon-Shiong said: “We are pleased to combine our expertise in human trials, T-Cell technology and our access to RNA manufacturing capacity with the Amyris and Infectious Disease Research Institute (IDRI) RNA technology platform and Amyris’ adjuvant technology.

“Combined, we have a real opportunity to provide true immunity against Covid-19 variants along with a platform that can quickly adapt to a future potential respiratory virus.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last November, ImmunityBio also entered a deal with Australian firm EnGeneIC for a Covid-19 vaccine and cancer therapy.

According to the deal, ImmunityBio obtained an exclusive, global licence from EnGeneIC to develop, produce and market the latter’s EnGeneIC Dream Vector (EDV) nano cell technology along with anti-cancer therapies and Covid-19 shot.

ImmunityBio obtained the South Africa Health Products Regulatory Authority (SAHPRA) approval to evaluate its dual-antigen T-cell vaccine for Covid-19 in Phase I/II/III South Africa Sisonke T-Cell Universal Boost trial in July last year.